“…1 Initially, β-blockers were divided into two generations based on receptor affinity: selective β-blockers such as metoprolol mostly affecting β 1 receptors in the heart, and non-selective β-blockers, propranolol for example, affecting both β 1 and β 2 receptors. 2 The selectivity of β-blockers, influencing their specific actions and potential side effects, varies across different generations of these drugs. 3 The third generation of β-blockers has demonstrated additional properties, including improved insulin resistance, and has been found to decrease cholesterol levels.…”